Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
N-Valeric acid, also known as valeric acid, is a straight chain saturated fatty acid containing five carbon atoms, with the chemical formula C5H10O2 and CAS number 109-52-4. As one of the common short chain fatty acids in natural products, valeric acid plays an important role in plant metabolism and is widely present in various plants and their extracts. In recent years, with the rapid development of natural product pharmacology, valeric acid has received increasing attention due to its potential sedative and hypnotic effects. Its mechanism of action involves multiple neurotransmitter receptors and transporters, especially targets related to serotonin receptors (HTR1A, HTR2A) and gamma aminobutyric acid receptors (GABRA1, GABRB2, GABRG2), indicating its importance in central nervous system regulation.
This review aims to systematically summarize the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation and pharmacokinetic characteristics of valeric acid, and explore its clinical application prospects and development potential in the field of sedation and hypnosis, providing theoretical basis and research direction for subsequent basic research and clinical translation.
The molecular formula of valeric acid is C5H10O2, with a molecular weight of 102.1330. Its structure is a straight chain composed of five carbon atoms, with a carboxyl group (- COOH) at the end, belonging to typical straight chain saturated fatty acids. This structure endows oxalic acid with a certain balance of hydrophobicity and hydrophilicity, with a LogP value of 1.0777, indicating that it has moderate lipid solubility, which is conducive to its diffusion and penetration in biofilms.
The polar surface area (TPSA) of valeric acid is 37.3 Å ², and its water solubility is 37.3614 mg/mL, indicating that it has good water solubility and is easy to absorb and distribute in vivo. Its blood-brain barrier permeability is low, indicating that the ability of oxalic acid to directly enter the central nervous system is limited, but it may act through indirect mechanisms or metabolites. In addition, valeric acid does not exhibit hERG channel inhibitory activity, and the Ames mutagenicity test result is 0, indicating its high safety and low toxicity risk.
Valeric acid, as a conjugated acid of valeric acid, has good chemical stability and is easy to exist in acidic and neutral environments, making it suitable for the development of various drug formulations.
Valerian acid is widely present in various plants, especially represented by plants of the genus Valeriana spp. Valerian acid and its derivatives are abundant in the roots, stems, and leaves of Valerian, and are important active ingredients in traditional herbal medicine. In addition to valerian, other plants such as certain leguminous and gramineous plants also contain a certain amount of valeric acid.
There are various methods for extracting valeric acid, including solvent extraction, distillation, and liquid-liquid extraction. The specific process often uses organic solvents such as ethanol, methanol, or ethyl acetate for extraction, followed by vacuum concentration and column chromatography purification to obtain high-purity valeric acid. In modern extraction techniques, ultrasound assisted extraction and microwave-assisted extraction have gradually been applied in the extraction process of valeric acid due to their high efficiency and energy-saving characteristics, effectively improving the extraction rate and purity.
In addition, the synthetic route of valeric acid is also relatively mature, which can be obtained through chemical synthesis or microbial fermentation in industrial production, meeting the needs of large-scale production.
The pharmacological activity of valeric acid is mainly concentrated in the central nervous system, especially exhibiting significant sedative and hypnotic effects. Early in vitro and in vivo experiments have shown that oxalic acid can regulate the release and receptor activity of neurotransmitters, improve symptoms of neurological and psychiatric disorders such as anxiety and insomnia.
Valenosic acid enhances inhibitory nerve conduction and exerts sedative hypnotic effects by regulating the functions of serotonin receptors (5-HT1A, 5-HT2A) and GABA_A receptor subunits (GABRA1, GABRB2, GABRG2). In animal experiments, oxalic acid significantly shortened sleep latency and prolonged sleep time, exhibiting characteristics similar to benzodiazepines, but with milder side effects.
Some studies have also shown that oxalic acid has anti-inflammatory and antioxidant effects, which help alleviate inflammation and oxidative stress in the nervous system, thereby protecting neurons and preventing the occurrence and development of neurodegenerative diseases.
As a short chain fatty acid, oxalic acid participates in energy metabolism and lipid metabolism regulation, affecting the ecological balance of gut microbiota, indirectly regulating central nervous system function, and demonstrating the potential of "gut brain axis" regulation.
The mechanism of action of valeric acid is mainly achieved through interactions with neurotransmitter receptors and transporters. Its targets mainly include:
The synergistic regulatory mechanism of these targets makes valeric acid a natural sedative hypnotic agent with multi-target effects, and has good safety and tolerability.
The pharmacological evaluation of valeric acid shows that it has good potential for drug development. Moderate molecular weight, reasonable LogP value, good water solubility, conducive to oral absorption. Although its blood-brain barrier permeability is low, it is expected to enhance the bioavailability of the central nervous system through metabolic conversion or adjuvant administration.
In terms of safety, oxalic acid has no significant hERG channel inhibitory effect, reducing the risk of cardiac toxicity; The Ames test is negative, indicating that it has no mutagenicity. Pharmacokinetic studies have shown that oxalic acid is widely distributed in the body, with metabolic pathways mainly through β - oxidation and esterification reactions. It is excreted rapidly and has a moderate half-life.
In the future, through structural modification and optimization of drug carrier technology, it is expected to further improve its pharmacokinetic properties, enhance efficacy and bioavailability.
Valeric acid, as a natural short chain fatty acid, has broad clinical application prospects due to its significant sedative and hypnotic effects and good safety. Its potential in treating insomnia, anxiety, and related mental disorders is increasingly being recognized, especially as an adjuvant therapy for mild to moderate neurological and psychiatric disorders.
Future research should focus on the following aspects:
In addition, the potential of oxalic acid in regulating intestinal microbiota and neuroprotection is also worth exploring, which may provide new ideas for the treatment of neurodegenerative and metabolic diseases.
In summary, as a natural short chain fatty acid, valeric acid has clear sedative and hypnotic pharmacological activities and good safety, involving the regulation of various neurotransmitter receptors and transporters. Its physical and chemical properties are suitable for drug development, and it has abundant plant sources and mature extraction processes. In the future, through systematic pharmacological mechanism research and clinical verification, oxalic acid is expected to become an important natural medicine for the treatment of neurological and psychiatric disorders, promoting the development of natural product pharmacology and neuropharmacology.
With the continuous deepening of interdisciplinary integration, the research on valeric acid will provide a solid scientific foundation for the development of new safe and efficient sedative hypnotic drugs, and promote the widespread application of natural products in modern medicine.
